aTyr Pharma
ATYR
24 hedge funds and large institutions have $7.68M invested in aTyr Pharma in 2019 Q1 according to their latest regulatory filings, with 2 funds opening new positions, 4 increasing their positions, 3 reducing their positions, and 3 closing their positions.
2,123% more capital inflows, than outflows
Capital inflows: $1.8M | Capital outflows: $80.8K
33% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 3
4.87% more ownership
Funds ownership: 35.3% → 40.17% (+4.9%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
4% less funds holding
Funds holding: 25 → 24 (-1)
33% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 3
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Viking Global Investors
Stamford,
Connecticut
|
+$929K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$720K |
| 3 |
Renaissance Technologies
New York
|
+$87.7K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$25.4K |
| 5 |
Virtu Financial
New York
|
+$21.1K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$49K |
| 2 |
Two Sigma Investments
New York
|
-$20.8K |
| 3 |
Macquarie Group
Sydney, NSW 2000,
Australia
|
-$9K |
| 4 |
BlackRock
New York
|
-$1.71K |
| 5 |
Morgan Stanley
New York
|
-$285 |
ATYR Hedge Fund Activity: Q1 2019 in Review
24 of the 4,634 institutional investors tracked by Wall St. Rank reported a position in aTyr Pharma (ATYR) for Q1 2019, worth a combined $7.68M — up 46% from $5.25M a quarter earlier.
Sellers outnumbered buyers: 3 funds closed out of ATYR and 2 opened new positions — a net loss of 1 holder — while 3 trimmed existing stakes and 4 added.
The largest buyer was Viking Global Investors, adding an estimated $929K. The largest seller was Susquehanna International Group, exiting entirely with an estimated $49K sold.
- 24 institutional investors held aTyr Pharma (ATYR) as of Q1 2019, down from 25 in Q4 2018.
- Funds reported $7.68M of aTyr Pharma stock for Q1 2019, up 46% quarter-over-quarter.
- 2 funds opened new aTyr Pharma positions in Q1 2019 and 3 closed out, a net change of -1 holder.
- The largest aTyr Pharma buyer in Q1 2019 was Viking Global Investors, an estimated $929K added.
- The largest aTyr Pharma seller in Q1 2019 was Susquehanna International Group, an estimated $49K sold.
Based on aggregated 13F filings for Q1 2019.